A photo of Michael Grimley.

Medical Director, Division of Bone Marrow Transplantation and Immune Deficiency

Professor, UC Department of Pediatrics

513-803-1969

Board Certified

"I believe that each patient is unique. I use a cooperative approach to treatment, in which I partner with the treatment team, the patient and their family."

My Biography & Research

Biography

I’ve been interested in medicine for as long as I can remember. My medical school experiences with the children solidified my feeling that pediatrics was the area I related to best.

Similarly, my exposure to pediatric and adult hematology/oncology patients and physicians in medical school confirmed that I wanted to work with these patients and colleagues.

As a bone marrow transplant physician, I believe that each patient is unique. I use a cooperative approach to treatment, in which I partner with the treatment team, the patient and their family.

My research involves finding treatments for and prevention of viral infections in immunocompromised patients.

When I’m not treating patients or involved in research, I enjoy spending time with my family.

Clinical Interests

Bone marrow transplantation for primary immunodeficiencies; cord blood transplants; leukemia

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Bone Marrow Transplantation BMT, Immune Deficiencies and Histiocytosis

Research Divisions

Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases

My Locations

My Education

MD: Emory University School of Medicine, Atlanta, GA, 1992.

Residency: Wilford Hall Medical Center, Lackland, AFB, TX, 1995.

Fellowship: Cincinnati Children’s Hospital Medical Center, 1999.

Certification: General Pediatrics, Pediatric Hematology/Oncology.

Licenses: Ohio, Texas.

My Publications

Ruxolitinib for the treatment of chronic GVHD and overlap syndrome in children and young adults. Wang, YM; Teusink-Cross, A; Elborai, Y; Krupski, MC; Nelson, AS; Grimley, MS; Flannery, A; Mehta, PA; Bleesing, JJ; Chandra, S; et al. Transplantation. 2021.

298 Ruxolitinib for the Treatment of Chronic GVHD in Children and Young Adults. Wang, YM; Teusink-Cross, A; Myers, KC; Davies, SM; Kumar, A; Chandra, S; Grimley, MS; Flannery, A; Krupski, MC; Nelson, AS; et al. 2021; 27:s257-s258.

Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. Watkins, B; Qayed, M; McCracken, C; Bratrude, B; Betz, K; Suessmuth, Y; Yu, A; Sinclair, S; Furlan, S; Bosinger, S; et al. Journal of Clinical Oncology. 2021.

Experience with a Reduced Toxicity Allogeneic Transplant Regimen for Non-CGD Primary Immune Deficiencies Requiring Myeloablation. Chandra, S; Chandrakasan, S; Dávila Saldaña, BJ; Bleesing, JJ; Jordan, MB; Kumar, AR; Grimley, MS; Krupski, C; Davies, SM; Khandelwal, P; et al. Journal of Clinical Immunology. 2021; 41:89-98.

Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients. Nelson, AS; Heyenbruch, D; Rubinstein, JD; Sabulski, A; Jodele, S; Thomas, S; Lutzko, C; Zhu, X; Leemhuis, T; Cancelas, JA; et al. Blood Advances. 2020; 4:5745-5754.

A Multi-Center Case Series, Systematic Review and Meta-Analysis of Neonatal Hemophagocytic Lymphohistiocytosis. Ebens, CL; DuVall, AS; DeFor, TE; Dimitrov, MT; Frame, D; Briones, MA; Grimley, M; Joshi, S; Marsh, RA; Shereck, E; et al. Blood. 2020; 136:19-20.

Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease. Shah, NC; Bhoopatiraju, S; Abraham, A; Anderson, EJ; Andreansky, M; Bhatia, M; Chaudhury, S; Cuvelier, GD E; Godder, K; Grimley, M; et al. Blood. 2020; 136:33-33.

Non-Tuberculous Mycobacterial Infection in Hematopoietic Cell Transplant. Sabulski, A; Davies, SM; Paulsen, G; Kumar, A; Grimley, M; Chandra, S. Journal of Clinical Immunology. 2020; 40:1171-1175.

CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II study. Khandelwal, P; Fukuda, T; Teusink-Cross, A; Kashuba, AD M; Lane, A; Mehta, PA; Marsh, RA; Jordan, MB; Grimley, MS; Myers, KC; et al. Bone Marrow Transplantation. 2020; 55:1552-1559.

Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy. Rubinstein, JD; Zhu, X; Lutzko, C; Leemhuis, T; Cancelas, JA; Jodele, S; Bollard, CM; Hanley, PJ; Davies, SM; Grimley, MS; et al. Blood Advances. 2020; 4:3252-3257.